I

Inter Pharma PCL
SET:IP

Watchlist Manager
Inter Pharma PCL
SET:IP
Watchlist
Price: 4.12 THB 0.49% Market Closed
Market Cap: ฿2.5B

EV/GP

3.6
Current
9%
Cheaper
vs 3-y average of 3.9

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
3.6
=
Enterprise Value
฿2.9B
/
Gross Profit
฿795m

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
3.6
=
Enterprise Value
฿2.9B
/
Gross Profit
฿795m

Valuation Scenarios

Inter Pharma PCL is trading below its 3-year average

If EV/GP returns to its 3-Year Average (3.9), the stock would be worth ฿4.54 (10% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+77%
Average Upside
38%
Scenario EV/GP Value Implied Price Upside/Downside
Current Multiple 3.6 ฿4.12
0%
3-Year Average 3.9 ฿4.54
+10%
5-Year Average 4.9 ฿5.63
+37%
Industry Average 4.5 ฿5.23
+27%
Country Average 6.3 ฿7.3
+77%

Forward EV/GP
Today’s price vs future gross profit

Not enough data available to calculate forward EV/GP

Peer Comparison

All Multiples
EV/GP
P/E
All Countries
Close
Market Cap EV/GP P/E
TH
Inter Pharma PCL
SET:IP
2.5B THB 3.6 34.7
FR
L'Oreal SA
PAR:OR
201.5B EUR 6.1 32.9
UK
Unilever PLC
LSE:ULVR
93.4B GBP 5.5 11.3
IN
Hindustan Unilever Ltd
NSE:HINDUNILVR
5.6T INR 16.2 37.6
UK
HALEON PLC
LSE:HLN
31.6B GBP 5.3 19
US
Estee Lauder Companies Inc
NYSE:EL
28.1B USD 3 -158.1
DE
Beiersdorf AG
XETRA:BEI
15.8B EUR 2.3 16.8
JP
Kao Corp
TSE:4452
2.7T JPY 3.7 22.2
IN
Godrej Consumer Products Ltd
NSE:GODREJCP
1.2T INR 14.9 64.1
CA
Relevium Technologies Inc
XTSX:RLV
12.2B CAD 4 939.9 -4 624.4
IN
Dabur India Ltd
NSE:DABUR
815.9B INR 12.2 43.3
P/E Multiple
Earnings Growth PEG
TH
I
Inter Pharma PCL
SET:IP
Average P/E: 31.3
34.7
N/A N/A
FR
L'Oreal SA
PAR:OR
32.9
13%
2.5
UK
Unilever PLC
LSE:ULVR
11.3
-6%
N/A
IN
Hindustan Unilever Ltd
NSE:HINDUNILVR
37.6
7%
5.4
UK
HALEON PLC
LSE:HLN
19
11%
1.7
US
Estee Lauder Companies Inc
NYSE:EL
Negative Multiple: -158.1 N/A N/A
DE
Beiersdorf AG
XETRA:BEI
16.8
6%
2.8
JP
Kao Corp
TSE:4452
22.2
10%
2.2
IN
Godrej Consumer Products Ltd
NSE:GODREJCP
64.1
18%
3.6
CA
Relevium Technologies Inc
XTSX:RLV
Negative Multiple: -4 624.4 N/A N/A
IN
Dabur India Ltd
NSE:DABUR
43.3
11%
3.9

Market Distribution

Lower than 79% of companies in Thailand
Percentile
21st
Based on 343 companies
21st percentile
3.6
Low
0.2 — 4.4
Typical Range
4.4 — 9.4
High
9.4 —
Distribution Statistics
Thailand
Min 0.2
30th Percentile 4.4
Median 6.3
70th Percentile 9.4
Max 220.6

Inter Pharma PCL
Glance View

Market Cap
2.5B THB
Industry
Consumer products

Inter Pharma PCL is engaged in biopharmaceutical business. The company is headquartered in Bangkok, Bangkok Metropolis. The company went IPO on 2019-11-05. The firm is principally engaged in the importing, manufacturing and distribution of dietary supplement product for humans and animals. The firm provides wellness and anti-aging products, aesthetic innovation products, animal health products and livestock products. Its wellness and anti-aging products include Probac7, Probac10 plus, TS6, Beta Glucan Plus, Pure Krill Oil, Astacurmin and YUUU Cleansing Mousse. Its aesthetic innovation products include Perfectha Complement, Perfectha Derm, Perfectha Deep and Perfectha Subskin. The Company’s animal health products include Dr.Choice Cal-B, Dr.Choice Cardi-B, Petinol, Pet Select Senior, Pet Select Osteoflex and Malaseb Shampoo for dogs and cats. The company also offers pet foods for dogs and cats. Its subsidiaries include Inter Vetta Co., Ltd., Modern Pharma Co., Ltd. and Inter Petrina Co., Ltd.

IP Intrinsic Value
2.63 THB
Overvaluation 36%
Intrinsic Value
Price ฿4.12
I
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett